Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study.
- Author:
Myung Ju AHN
1
;
Ho Suck OH
;
Jung Hye CHOI
;
Young Yeul LEE
;
In Soon KIM
;
Il Young CHOI
;
Oh Young LEE
;
Ho Soon CHOI
;
Sung Joon KWON
Author Information
1. Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. ahnmj@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Gastric neoplasm;
Combination chemotherapy;
Heptaplatin;
Paclifaxel;
5-fluorouracil
- MeSH:
Aged;
Anemia;
Disease Progression;
Drug Therapy, Combination*;
Fluorouracil*;
Follow-Up Studies;
Humans;
Liver;
Lymph Nodes;
Neoplasm Metastasis;
Neutropenia;
Paclitaxel*;
Pilot Projects*;
Pneumonia;
Stomach Neoplasms*;
Thrombocytopenia
- From:Cancer Research and Treatment
2004;36(3):182-186
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. MATERIALS AND METHODS: Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m(2) iv on day 1, heptaplatin 400 mg/m(2) iv on day 2 and 5-fluorouracil 800 mg/m(2) on day 2~4 were administered and the regimen was repeated every 3 weeks. RESULTS: The median age of the patients was 60 years (range: 32~74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26~8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48~6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26~17.44). A median of 3 cycles (range: 1~7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life- threatening complication of pneumonia. CONCLUSION: The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.
